MIR200B (MicroRNA 200b)

News alerts, weekly reports and conference planners

Entrez ID:

miR-200-b overexpression	Non Small Cell Lung Cancer	miR-200-b overexpression	Non Small Cell Lung Cancer	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
miR-200-b overexpression	Non Small Cell Lung Cancer	miR-200-b overexpression	Non Small Cell Lung Cancer	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3
miR-200-b expression	Pancreatic Cancer	miR-200-b expression	Pancreatic Cancer	erlotinib + mirdametinib Sensitive: D – Preclinical erlotinib + mirdametinib Sensitive : D	erlotinib + mirdametinib Sensitive: D – Preclinical erlotinib + mirdametinib Sensitive : D
miR-200-b underexpression	Gastric Cancer	miR-200-b underexpression	Gastric Cancer	5-fluorouracil Resistant: D – Preclinical 5-fluorouracil Resistant : D	5-fluorouracil Resistant: D – Preclinical 5-fluorouracil Resistant : D
miR-200b underexpression + miR-103a underexpression	Gastric Cancer	miR-200b underexpression + miR-103a underexpression	Gastric Cancer	5-fluorouracil Resistant: D – Preclinical 5-fluorouracil Resistant : D	5-fluorouracil Resistant: D – Preclinical 5-fluorouracil Resistant : D

Associations(5)